Perspective Therapeutics, Inc.
CATXNYSE
$2.99
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↓ -26.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$309.8M
Enterprise Value
$40.5M
P/E
—
P/S
—
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
-34.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$111.1M
Free Cash Flow (TTM)
-$107.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-32.0%
ROIC
-121.4%
Debt / Equity
0.0
Net Cash
$269.3M
Return 1Y
-27.6%
Company profile
Isoray, Inc. develops, manufactures, and sells isotope-based medical products and devices. CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.
- CEO
- Lori A. Woods
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 70
- Headquarters
- Washington
- Website
- isoray.com
Management & directors
- Hunt Jonathan RobertChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
CATX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.250.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.1M | $10.8M | $0.00 | $1.4M | — | — |
| Gross profit | $5.1M | $0.00 | $0.00 | $1.4M | — | — |
| Operating income | -$3.4M | -$6.4M | -$8.7M | -$40.9M | -$90.9M | -$113.6M |
| Net income | -$3.4M | -$7.3M | -$10.8M | -$46.5M | -$79.3M | -$103.1M |
| Diluted EPS | — | — | — | -$1.74 | -$1.23 | -$1.40 |
| Operating cash flow | -$2.8M | -$7.7M | -$10.4M | -$36.9M | -$18.3M | -$82.5M |
| Free cash flow | -$3.2M | -$8.0M | -$10.7M | -$38.0M | -$72.7M | -$95.2M |
| Gross margin | 50.9% | 0.0% | — | 100.0% | — | — |
| Operating margin | -34.3% | -59.5% | — | -2855.0% | — | — |
| Net margin | -33.7% | -67.4% | — | -3243.2% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.3M | -$18.6M | -$45.0M | -$21.8M | -$24.0M | -$27.9M | -$39.8M | -$28.3M |
| Net income | -$11.7M | -$15.1M | -$40.2M | -$18.2M | -$21.5M | -$26.0M | -$37.5M | -$26.2M |
| Diluted EPS | -$0.18 | -$0.21 | -$0.59 | -$0.25 | -$0.29 | -$0.35 | -$0.51 | -$0.25 |
| Operating cash flow | -$8.9M | $3.4M | -$26.6M | -$21.6M | -$20.0M | -$16.3M | -$24.7M | -$31.5M |
| Free cash flow | -$9.9M | -$26.3M | -$41.2M | -$26.2M | -$21.0M | -$18.3M | -$29.7M | -$38.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Jun 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-13 | Hunt Jonathan Robert· Chief Accounting Officer | Buy | 11,000 | $2.03 | $22,294.80 | filing |
| 2025-11-12 | Williamson Robert F III | Buy | 9,498 | $2.10 | $19,945.80 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.